about
A cohort study of interstitial lung diseases in central DenmarkUnclassifiable interstitial lung diseases: Clinical characteristics and survivalOrganisation of diagnosis and treatment of idiopathic pulmonary fibrosis and other interstitial lung diseases in the Nordic countries.A cohort study of Danish patients with interstitial lung diseases: burden, severity, treatment and survival.Hypersensitivity pneumonitis among wind musicians - an overlooked disease?A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality.No effect of pirfenidone treatment in fulminant bleomycin-induced pneumonitis.Co-morbidity and mortality among patients with interstitial lung diseases: A population-based study.[Idiopathic pulmonary fibrosis is an overlooked disease].[Prevalence, symptoms, and diagnosis of tuberculosis in Denmark].How does comorbidity influence survival in idiopathic pulmonary fibrosis?[Diagnostic criteria and possible treatment of idiopathic pulmonary fibrosis].An unusual presentation of sarcoidosis with tetraplegia and severe osteolytic bone lesions.Economic consequences of idiopathic pulmonary fibrosis in Denmark.Clinical characteristics and outcome in patients with antisynthetase syndrome associated interstitial lung disease: a retrospective cohort studyValue of s-ACE, BAL lymphocytosis, and CD4+/CD8+ and CD103+CD4+/CD4+ T-cell ratios in diagnosis of sarcoidosisIncreased mortality among patients with rheumatoid arthritis and COPD: A population-based study[Individualised treatment of patients with bronchoectasis]Rheumatoid Arthritis-Associated Interstitial Lung Disease: Clinical Characteristics and Predictors of MortalityInterstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians
P50
Q28236066-E51AACD9-4194-4096-8262-C563DFA609CAQ30160724-66680DE4-B599-4EE6-BE4A-F6CAECFFFB5FQ36239414-F9E07E7D-6C23-4264-8E08-2F0FDACF4390Q38420560-2F5E26A8-D09C-4B15-BFBC-0533E64421A3Q38621261-9C01A2F0-3CC8-4FFF-A79C-D24BC50CE20FQ38727065-C3A184CD-ABE1-4D1B-93D6-CA57CC3B01DAQ40823919-BA127454-9C45-4398-841A-FFD0EA7A634AQ47678274-AE21943C-97B5-46BC-8A04-2818DD320FB5Q50008698-EC25F53A-683D-4E30-BC46-7917536E964AQ50553469-6906DC0A-9938-4574-B6A5-6BC037A00F08Q50721660-0D90B957-16B0-4F73-A21B-CF950CD023EDQ53043221-3AC46558-6681-497E-82F4-4D0D3B176FA6Q53234391-7230171A-447A-42C3-98C6-BF5090ACFF88Q55311568-857A561A-78F0-4E17-B2A0-61AFDBC006C5Q64094676-8A3F02F7-42B2-4392-8C47-E7361176EFC0Q83787810-6A4D0927-F81C-4596-AA0D-BEF6B6AA6B5EQ89344462-970D599B-955C-4598-819E-58B9943A71A9Q90301623-6DCD96EB-FA57-4D35-B82E-59B0F31858C2Q90612564-76185EC5-5AE3-455F-9BF1-D4F3D1913749Q91444417-4A9E42F1-6BF3-4BDF-982F-6FAFAF341E72
P50
description
investigador
@es
researcher
@en
name
Charlotte Hyldgaard
@en
Charlotte Hyldgaard
@es
type
label
Charlotte Hyldgaard
@en
Charlotte Hyldgaard
@es
prefLabel
Charlotte Hyldgaard
@en
Charlotte Hyldgaard
@es
P31
P496
0000-0002-6353-8671